GKOS
Glaukos Corporation · Healthcare
Insiders sold $67.3M of Glaukos Corporation in the last 12 months and bought none
GKOS over the last year
GKOS after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Every filing
150 insider filings since 2016, newest first
Tomas Navratil · Chief Development Officer
Tomas Navratil · Chief Development Officer
Tomas Navratil · Chief Development Officer
Tomas Navratil · Chief Development Officer
Gilbert H Kliman · Director
Joseph E Gilliam · President and COO
Alex R. Thurman · SVP and Chief Financial Officer
Leana Wen · Director
Alex R. Thurman · SVP and Chief Financial Officer
Alex R. Thurman · SVP and Chief Financial Officer
Alex R. Thurman · SVP and Chief Financial Officer
Tomas Navratil · Chief Development Officer
Tomas Navratil · Chief Development Officer
Gilbert H Kliman · Director
Gilbert H Kliman · Director
Alex R. Thurman · SVP and CFO
Joseph E Gilliam · President and COO
Tomas Navratil · Chief Development Officer
Alex R. Thurman · SVP and CFO
Alex R. Thurman · SVP and CFO
Tomas Navratil · Chief Development Officer
Alex R. Thurman · SVP and CFO
Aimee S Weisner · Director
Joseph E Gilliam · President and COO
Marc Stapley · Director
Joseph E Gilliam · President and COO
Thomas William Burns · Chair and CEO
Gilbert H Kliman · Director
Alex R. Thurman · SVP and CFO
Joseph E Gilliam · President and COO
Gilbert H Kliman · Director
Joseph E Gilliam · President and COO
Marc Stapley · Director
Aimee S Weisner · Director
Joseph E Gilliam · President and COO
Joseph E Gilliam · President and COO
Gilbert H Kliman · Director
Marc Stapley · Director
Joseph E Gilliam · President and COO
Alex R. Thurman · SVP and CFO
Alex R. Thurman · SVP and CFO
Joseph E Gilliam · President and COO
Joseph E Gilliam · President and COO
Alex R. Thurman · SVP and CFO
Joseph E Gilliam · President and COO
Joseph E Gilliam · President and COO
Alex R. Thurman · SVP and CFO
Alex R. Thurman · SVP and CFO
Gilbert H Kliman · Director
Marc Stapley · Director
About Glaukos Corporation
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.